Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HaiHe Pharma Forms Drug Development/Marketing JV with CSPC

publication date: Feb 19, 2019

Shanghai HaiHe Pharma formed a JV with CSPC Pharma, a Shijiazhuang state-owned company, which will develop and commercialize five HaiHe clinical stage candidates. The assets include two cancer pain drugs, an anti-infective and two cancer treatments. One week ago, HaiHe announced it raised $146.6 million to support its portfolio. HaiHe merged with RMX Biopharma in 2018. HaiHe is conducting clinical trials on ten molecules and has five more in pre-clinical studies. More details....

Stock Symbol: (HK: 1093)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.